Exosomal proteins in prostate cancer progression: from mechanisms to diagnostic and therapeutic applications

Prostate cancer (PCa) remains a leading cause of cancer death in men, and the limitations of prostate-specific antigen (PSA) testing continue to delay diagnosis and confound risk stratification. Exosomes, small extracellular vesicles that can be recovered non-invasively from blood and urine, provide a window onto tumour biology, and the proteins they carry are the most readily measurable of their cargoes for clinical assay development. This review summarises how exosomal proteins sustain four programmes that jointly drive PCa progression: Wnt/β-catenin-dependent metastasis, angiogenesis, immune evasion and the suppression of ferroptosis, the iron-dependent, lipid-peroxidation-driven cell death to which treatment-resistant PCa is vulnerable. Each protein is considered together with its cell of origin, carcinoma cells, cancer-associated fibroblasts or tumour-associated macrophages, because the same molecule can act differently depending on the cell that released it. Key examples include GIPC2, which engages the Wnt co-receptor Fzd7 to activate β-catenin signalling; PGAM1, which binds γ-actin in endothelial cells to promote angiogenesis; exosomal PD-1 and PD-L1, which respectively activate myeloid-derived suppressor cells and suppress CD8 + T cells; and FTH1P8 together with CAF-derived miR-432–5p, which blunt ferroptosis and sustain docetaxel and antiandrogen resistance. The review also covers the diagnostic value of urinary exosomal proteins such as PSMA and PSA, the difference between these protein markers and the RNA-based ExoDx EPI test, and the emerging advances, from GMP-compliant manufacturing and single-vesicle quantification to regulatory guidance, that are beginning to overcome the barriers of isolation heterogeneity, scalability, immunogenicity and regulation.

Authors

Institutions

Publication Details

Journal
Frontiers in Cell and Developmental Biology
Published
2026-11-12
DOI
https://doi.org/10.3389/fcell.2026.1954925
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Exosomal proteins in prostate cancer progression: from mechanisms to diagnostic and therapeutic applications

Yuhe Huang, Ziyi Song, Daojun Lv, Yitao Wang
Frontiers in Cell and Developmental Biology
Extracellular vesicles in disease
article

Exosomal proteins in prostate cancer progression: from mechanisms to diagnostic and therapeutic applications

Yuhe Huang, Ziyi Song, Daojun Lv, Yitao Wang
article en

Abstract

Prostate cancer (PCa) remains a leading cause of cancer death in men, and the limitations of prostate-specific antigen (PSA) testing continue to delay diagnosis and confound risk stratification. Exosomes, small extracellular vesicles that can be recovered non-invasively from blood and urine, provide a window onto tumour biology, and the proteins they carry are the most readily measurable of their cargoes for clinical assay development. This review summarises how exosomal proteins sustain four programmes that jointly drive PCa progression: Wnt/β-catenin-dependent metastasis, angiogenesis, immune evasion and the suppression of ferroptosis, the iron-dependent, lipid-peroxidation-driven cell death to which treatment-resistant PCa is vulnerable. Each protein is considered together with its cell of origin, carcinoma cells, cancer-associated fibroblasts or tumour-associated macrophages, because the same molecule can act differently depending on the cell that released it. Key examples include GIPC2, which engages the Wnt co-receptor Fzd7 to activate β-catenin signalling; PGAM1, which binds γ-actin in endothelial cells to promote angiogenesis; exosomal PD-1 and PD-L1, which respectively activate myeloid-derived suppressor cells and suppress CD8 + T cells; and FTH1P8 together with CAF-derived miR-432–5p, which blunt ferroptosis and sustain docetaxel and antiandrogen resistance. The review also covers the diagnostic value of urinary exosomal proteins such as PSMA and PSA, the difference between these protein markers and the RNA-based ExoDx EPI test, and the emerging advances, from GMP-compliant manufacturing and single-vesicle quantification to regulatory guidance, that are beginning to overcome the barriers of isolation heterogeneity, scalability, immunogenicity and regulation.

Frontiers in Cell and Developmental BiologyVol. 14
Third Affiliated Hospital of Guangzhou Medical University (CN), Guangzhou Medical University (CN)
National Natural Science Foundation of China
Good health and well-being
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon